April 24, 2018 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2017. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, www.indexpharma.com
The printed Annual Report is mailed to shareholders and other stakeholders who specifically request it. Send request to firstname.lastname@example.org, or by mail to InDex Pharmaceuticals Holding AB (publ), Tomtebodavägen 23a, 171 77 Stockholm.
For more information:
Phone: +46 8 508 847 35
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com
This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication through the agency of the contact person set out above at 8:00 CET on April 24, 2018.
- InDex Pharmaceuticals Holding AB - Annual Report 2017 - 24 April 2018 - Swedish
- Press release - InDex Pharmaceuticals Holding AB publishes Annual Report for 2017 - 24 April 2018 - English